Volume Alert - ACT 261.24 Actavis Inc $ACT Hit a h
Post# of 91
Posted On: 11/18/2014 11:28:44 AM
Volume Alert - ACT 261.24 Actavis Inc $ACT Hit a high today of 264.00 Closing the day 10:30 at 261.24 +13.30 +5.36% With a day low of 249.86 and a total volume of 4,598,087.
ACT Recent Posts: http://investorshangout.com/Actavis-Inc-ACT-53105/
ACT Actavis Inc Recent Headline News
Actavis (ACT) Is Today's Unusual Social Activity Stock
at The Street - 14 mins ago
Trade-Ideas LLC identified Actavis (ACT) as an unusual social activity candidate
ACT: 260.23 (+12.29)
One Factor Driving Up Actavis (ACT) Stock Today
at The Street - 22 mins ago
Actavis (ACT) shares continue to climb as analysts at Citigroup (C) raised the company's price target following its purchase of Allergan (AGN) for $66 billion.
ACT: 260.33 (+12.39)
Stock Market News for November 18, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - 1 hr 18 mins ago
Markets ended its choppy run yesterday on a mixed note after Japan unexpectedly slipped into a recession
AGN: 212.10 (+2.90), ACT: 260.33 (+12.39), EOG: 97.17 (+0.82), HAL: 49.59 (+0.36), HP: 77.44 (-0.81), MRO: 31.90 (+0.08), BHI: 65.76 (+0.53)
Will Pfizer's Dividend Be Safe?
Todd Campbell, The Motley Fool - Motley Fool - 1 hr 59 mins ago
Source: Pfizer via Facebook. Pfizer (NYSE: PFE) may be one of the planet's largest drugmakers, but it's been navigating a series of sales-crunching patent expirations that has investors wondering if the company's dividend payout will remain...
ACT: 260.33 (+12.39), PFE: 30.57 (+0.25), TEVA: 57.44 (+0.20)
Winners And Losers In The Allergan Valeant Actavis Melee; Also, Will Bill Ackman Lose His Profit?
Uncommon Profit Investor - at Seeking Alpha - 2 hrs 55 mins ago
AGN: 212.00 (+2.80), VRX: 141.24 (+4.51), ACT: 260.33 (+12.39)
Here Are Some Big Caps Poised To Make Gains
at Investor's Business Daily - Mon Nov 17, 5:45PM CST
Several Big Cap 20 stocks have recently broken out of bases, but are still within buy range, or are building new bases and could be good additions to a watch list. Alexion Pharmaceuticals (ALXN) has pulled back and is within the 5% buy zone. The...
AGN: 212.00 (+2.80), ACT: 260.33 (+12.39), VRX: 141.24 (+4.51), V: 250.52 (+0.72), ALXN: 190.26 (+3.48), CTSH: 52.76 (-0.30), MA: 83.66 (+0.46), ADS: 282.56 (+1.68)
Bristol-Myers Squibb Reports Positive Opdivo Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:20PM CST
Bristol-Myers Squibb Company announced encouraging data from the phase III CheckMate - 066 study on immuno-oncology drug Opdivo.
AGN: 212.00 (+2.80), ACT: 260.33 (+12.39), AMAG: 36.27 (+1.51), BMY: 58.69 (+0.26)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 4:40PM CST
URBN: 27.99 (-2.84), DHX: 11.32 (+0.06), ACT: 260.33 (+12.39), OME: 12.43 (-2.55), CLVS: 53.47 (+0.14), AVB: 158.37 (+0.21), PF: 32.42 (-1.30), RMTI: 10.31 (-0.27), GLW: 20.45 (+0.09), FOLD: 6.33 (-0.37)
Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
1 Comment
DRTX: 24.16 (+0.41), AGN: 212.00 (+2.80), ACT: 260.33 (+12.39), VRX: 141.24 (+4.51), MRK: 59.86 (+0.40), VRX.TO: 159.70 (+5.30)
Stocks End Mixed As Allergan Jumps On Actavis Deal
at Investor's Business Daily - Mon Nov 17, 3:16PM CST
Major averages pared losses from a late-morning slump to end mixed amid big merger deals and weak economic data. The S&P 500 and Dow Jones industrial average closed fractionally higher, while the Nasdaq fell 0.4%. Volume ran lower across the board in...
AGN: 212.00 (+2.80), VRX: 141.24 (+4.51), ACT: 260.33 (+12.39), SAFM: 86.42 (+1.49), PPC: 31.21 (+0.27), MIK: 21.99 (+0.34), TSN: 42.31 (-0.72)
Stock Market Today: Japan Recession Keeps Markets From Celebrating Deals Deluge
at The Street - Mon Nov 17, 3:15PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies momentarily distracts Wall Street from worrying news Japan has fallen into recession in its third quarter.
AMZN: 327.57 (+4.52), HAS: 55.97 (-0.40), ACT: 260.33 (+12.39), VRX: 141.24 (+4.51), JIVE: 6.41 (+0.04), FB: 74.37 (+0.13), HAL: 49.60 (+0.37), DWA: 22.18 (-0.13), AGN: 212.00 (+2.80), LNKD: 224.68 (+1.40), BHI: 65.75 (+0.52), CRM: 63.02 (+0.51)
Stocks Mixed In Afternoon; Allergan Jumps To New High
at Investor's Business Daily - Mon Nov 17, 2:13PM CST
Stocks remained mixed late Monday afternoon as investors weighed a spate of merger activity against news that Japan fell into a recession. The Dow Jones industrial average and the S&P 500 were each up 0.1%, while the Nasdaq was down 0.3%. Volume was...
AGN: 212.00 (+2.80), VRX: 141.24 (+4.51), ACT: 260.33 (+12.39), LNKD: 224.68 (+1.40), FB: 74.37 (+0.13), HAL: 49.60 (+0.37), BHI: 65.75 (+0.52), Z: 117.43 (-0.43)
Stock Market Today: Stocks Are Mixed as Corporate Deals Offset Japan's Recession
at The Street - Mon Nov 17, 12:16PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies distract Wall Street from worrying news Japan had fallen into recession in its third quarter.
AGN: 212.00 (+2.80), HAS: 55.97 (-0.40), AMZN: 327.57 (+4.52), VRX: 141.24 (+4.51), ACT: 260.33 (+12.39), LNKD: 224.68 (+1.40), JIVE: 6.41 (+0.04), FB: 74.36 (+0.12), HAL: 49.60 (+0.37), DWA: 22.18 (-0.13), CRM: 63.02 (+0.51), BHI: 65.75 (+0.52)
Pershing Square wins big on Actavis buy
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:22AM CST
AGN: 212.00 (+2.80), ACT: 260.33 (+12.39), VRX: 141.24 (+4.51)
Cramer: Investors Should Ignore Analysts' Calls on Hotel, Other Stocks
at The Street - Mon Nov 17, 10:32AM CST
Analysts have been growing pessimistic on several high quality stocks and sectors. Investors should use weakness as a buying opportunity instead, Cramer said.
AGN: 212.00 (+2.80), ACT: 260.33 (+12.39), PG: 87.96 (+0.12), MAR: 76.71 (-0.46), HOT: 77.41 (+0.56)
Allergan's $66 Billion Actavis Deal is Still a Win for Bill Ackman
at The Street - Mon Nov 17, 9:59AM CST
Valeant says it can't justify $219 a share offer to shareholders.
ZTS: 43.65 (-0.58), AGN: 212.00 (+2.80), VRX: 141.24 (+4.51), ACT: 260.33 (+12.39)
Stock Market Today: Stocks Shrug Off Japan's Recession as Deals Dominate Day
at The Street - Mon Nov 17, 9:40AM CST
U.S. stocks recover from earlier lows triggered by Japan's recession. Deals news about Baker Hughes and Allergan dominate headlines.
AGN: 212.00 (+2.80), HAS: 55.97 (-0.40), ACT: 260.33 (+12.39), HAL: 49.60 (+0.37), DWA: 22.18 (-0.13), BHI: 65.75 (+0.52)
ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Mon Nov 17, 9:32AM CST
Rigrodsky & Long, P.A.:
AGN: 212.00 (+2.80), ACT: 260.33 (+12.39)
Actavis Nabs Allergan For $66 Billion; Valeant Folds
at Investor's Business Daily - Mon Nov 17, 9:17AM CST
One of the most widely rumored deals in pharma came to fruition Monday, as Actavis (ACT) agreed to acquire Allergan (AGN) for $66 billion in cash and stock. Allergan stock was up more than 7%, near 213, and Actavis stock up nearly 4%, near 253, in...
AGN: 212.00 (+2.80), VRX: 141.24 (+4.51), ACT: 260.33 (+12.39)
Time to move on: Valeant chief says $219 too rich
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 9:13AM CST
ACT: 260.33 (+12.39), VRX: 141.24 (+4.51)
ACT Recent Posts: http://investorshangout.com/Actavis-Inc-ACT-53105/
ACT Actavis Inc Recent Headline News
Actavis (ACT) Is Today's Unusual Social Activity Stock
at The Street - 14 mins ago
Trade-Ideas LLC identified Actavis (ACT) as an unusual social activity candidate
ACT: 260.23 (+12.29)
One Factor Driving Up Actavis (ACT) Stock Today
at The Street - 22 mins ago
Actavis (ACT) shares continue to climb as analysts at Citigroup (C) raised the company's price target following its purchase of Allergan (AGN) for $66 billion.
ACT: 260.33 (+12.39)
Stock Market News for November 18, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - 1 hr 18 mins ago
Markets ended its choppy run yesterday on a mixed note after Japan unexpectedly slipped into a recession
AGN: 212.10 (+2.90), ACT: 260.33 (+12.39), EOG: 97.17 (+0.82), HAL: 49.59 (+0.36), HP: 77.44 (-0.81), MRO: 31.90 (+0.08), BHI: 65.76 (+0.53)
Will Pfizer's Dividend Be Safe?
Todd Campbell, The Motley Fool - Motley Fool - 1 hr 59 mins ago
Source: Pfizer via Facebook. Pfizer (NYSE: PFE) may be one of the planet's largest drugmakers, but it's been navigating a series of sales-crunching patent expirations that has investors wondering if the company's dividend payout will remain...
ACT: 260.33 (+12.39), PFE: 30.57 (+0.25), TEVA: 57.44 (+0.20)
Winners And Losers In The Allergan Valeant Actavis Melee; Also, Will Bill Ackman Lose His Profit?
Uncommon Profit Investor - at Seeking Alpha - 2 hrs 55 mins ago
AGN: 212.00 (+2.80), VRX: 141.24 (+4.51), ACT: 260.33 (+12.39)
Here Are Some Big Caps Poised To Make Gains
at Investor's Business Daily - Mon Nov 17, 5:45PM CST
Several Big Cap 20 stocks have recently broken out of bases, but are still within buy range, or are building new bases and could be good additions to a watch list. Alexion Pharmaceuticals (ALXN) has pulled back and is within the 5% buy zone. The...
AGN: 212.00 (+2.80), ACT: 260.33 (+12.39), VRX: 141.24 (+4.51), V: 250.52 (+0.72), ALXN: 190.26 (+3.48), CTSH: 52.76 (-0.30), MA: 83.66 (+0.46), ADS: 282.56 (+1.68)
Bristol-Myers Squibb Reports Positive Opdivo Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:20PM CST
Bristol-Myers Squibb Company announced encouraging data from the phase III CheckMate - 066 study on immuno-oncology drug Opdivo.
AGN: 212.00 (+2.80), ACT: 260.33 (+12.39), AMAG: 36.27 (+1.51), BMY: 58.69 (+0.26)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 4:40PM CST
URBN: 27.99 (-2.84), DHX: 11.32 (+0.06), ACT: 260.33 (+12.39), OME: 12.43 (-2.55), CLVS: 53.47 (+0.14), AVB: 158.37 (+0.21), PF: 32.42 (-1.30), RMTI: 10.31 (-0.27), GLW: 20.45 (+0.09), FOLD: 6.33 (-0.37)
Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
1 Comment
DRTX: 24.16 (+0.41), AGN: 212.00 (+2.80), ACT: 260.33 (+12.39), VRX: 141.24 (+4.51), MRK: 59.86 (+0.40), VRX.TO: 159.70 (+5.30)
Stocks End Mixed As Allergan Jumps On Actavis Deal
at Investor's Business Daily - Mon Nov 17, 3:16PM CST
Major averages pared losses from a late-morning slump to end mixed amid big merger deals and weak economic data. The S&P 500 and Dow Jones industrial average closed fractionally higher, while the Nasdaq fell 0.4%. Volume ran lower across the board in...
AGN: 212.00 (+2.80), VRX: 141.24 (+4.51), ACT: 260.33 (+12.39), SAFM: 86.42 (+1.49), PPC: 31.21 (+0.27), MIK: 21.99 (+0.34), TSN: 42.31 (-0.72)
Stock Market Today: Japan Recession Keeps Markets From Celebrating Deals Deluge
at The Street - Mon Nov 17, 3:15PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies momentarily distracts Wall Street from worrying news Japan has fallen into recession in its third quarter.
AMZN: 327.57 (+4.52), HAS: 55.97 (-0.40), ACT: 260.33 (+12.39), VRX: 141.24 (+4.51), JIVE: 6.41 (+0.04), FB: 74.37 (+0.13), HAL: 49.60 (+0.37), DWA: 22.18 (-0.13), AGN: 212.00 (+2.80), LNKD: 224.68 (+1.40), BHI: 65.75 (+0.52), CRM: 63.02 (+0.51)
Stocks Mixed In Afternoon; Allergan Jumps To New High
at Investor's Business Daily - Mon Nov 17, 2:13PM CST
Stocks remained mixed late Monday afternoon as investors weighed a spate of merger activity against news that Japan fell into a recession. The Dow Jones industrial average and the S&P 500 were each up 0.1%, while the Nasdaq was down 0.3%. Volume was...
AGN: 212.00 (+2.80), VRX: 141.24 (+4.51), ACT: 260.33 (+12.39), LNKD: 224.68 (+1.40), FB: 74.37 (+0.13), HAL: 49.60 (+0.37), BHI: 65.75 (+0.52), Z: 117.43 (-0.43)
Stock Market Today: Stocks Are Mixed as Corporate Deals Offset Japan's Recession
at The Street - Mon Nov 17, 12:16PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies distract Wall Street from worrying news Japan had fallen into recession in its third quarter.
AGN: 212.00 (+2.80), HAS: 55.97 (-0.40), AMZN: 327.57 (+4.52), VRX: 141.24 (+4.51), ACT: 260.33 (+12.39), LNKD: 224.68 (+1.40), JIVE: 6.41 (+0.04), FB: 74.36 (+0.12), HAL: 49.60 (+0.37), DWA: 22.18 (-0.13), CRM: 63.02 (+0.51), BHI: 65.75 (+0.52)
Pershing Square wins big on Actavis buy
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:22AM CST
AGN: 212.00 (+2.80), ACT: 260.33 (+12.39), VRX: 141.24 (+4.51)
Cramer: Investors Should Ignore Analysts' Calls on Hotel, Other Stocks
at The Street - Mon Nov 17, 10:32AM CST
Analysts have been growing pessimistic on several high quality stocks and sectors. Investors should use weakness as a buying opportunity instead, Cramer said.
AGN: 212.00 (+2.80), ACT: 260.33 (+12.39), PG: 87.96 (+0.12), MAR: 76.71 (-0.46), HOT: 77.41 (+0.56)
Allergan's $66 Billion Actavis Deal is Still a Win for Bill Ackman
at The Street - Mon Nov 17, 9:59AM CST
Valeant says it can't justify $219 a share offer to shareholders.
ZTS: 43.65 (-0.58), AGN: 212.00 (+2.80), VRX: 141.24 (+4.51), ACT: 260.33 (+12.39)
Stock Market Today: Stocks Shrug Off Japan's Recession as Deals Dominate Day
at The Street - Mon Nov 17, 9:40AM CST
U.S. stocks recover from earlier lows triggered by Japan's recession. Deals news about Baker Hughes and Allergan dominate headlines.
AGN: 212.00 (+2.80), HAS: 55.97 (-0.40), ACT: 260.33 (+12.39), HAL: 49.60 (+0.37), DWA: 22.18 (-0.13), BHI: 65.75 (+0.52)
ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Mon Nov 17, 9:32AM CST
Rigrodsky & Long, P.A.:
AGN: 212.00 (+2.80), ACT: 260.33 (+12.39)
Actavis Nabs Allergan For $66 Billion; Valeant Folds
at Investor's Business Daily - Mon Nov 17, 9:17AM CST
One of the most widely rumored deals in pharma came to fruition Monday, as Actavis (ACT) agreed to acquire Allergan (AGN) for $66 billion in cash and stock. Allergan stock was up more than 7%, near 213, and Actavis stock up nearly 4%, near 253, in...
AGN: 212.00 (+2.80), VRX: 141.24 (+4.51), ACT: 260.33 (+12.39)
Time to move on: Valeant chief says $219 too rich
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 9:13AM CST
ACT: 260.33 (+12.39), VRX: 141.24 (+4.51)
(0)
(0)Allergan plc (AGN) Stock Research Links
Scroll down for more posts ▼